Full Text:   <148>

Summary:  <35>

Suppl. Mater.: 

CLC number: R733.71

On-line Access: 2020-09-07

Received: 2019-12-30

Revision Accepted: 2020-06-17

Crosschecked: 2020-08-17

Cited: 0

Clicked: 233

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Jie Jin

https://orcid.org/0000-0002-8166-9915

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2020 Vol.21 No.9 P.740-744

http://doi.org/10.1631/jzus.B1900719


Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients


Author(s):  Shan-shan Suo, Chen-ying Li, Yi Zhang, Jing-han Wang, Yin-jun Lou, Wen-juan Yu, Jie Jin

Affiliation(s):  Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; more

Corresponding email(s):   jiej0503@zju.edu.cn

Key Words:  Acute lymphoblastic leukemia, Diabetes mellitus, Clinical characteristics


Shan-shan Suo, Chen-ying Li, Yi Zhang, Jing-han Wang, Yin-jun Lou, Wen-juan Yu, Jie Jin. Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients[J]. Journal of Zhejiang University Science B, 2020, 21(9): 740-744.

@article{title="Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients",
author="Shan-shan Suo, Chen-ying Li, Yi Zhang, Jing-han Wang, Yin-jun Lou, Wen-juan Yu, Jie Jin",
journal="Journal of Zhejiang University Science B",
volume="21",
number="9",
pages="740-744",
year="2020",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1900719"
}

%0 Journal Article
%T Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients
%A Shan-shan Suo
%A Chen-ying Li
%A Yi Zhang
%A Jing-han Wang
%A Yin-jun Lou
%A Wen-juan Yu
%A Jie Jin
%J Journal of Zhejiang University SCIENCE B
%V 21
%N 9
%P 740-744
%@ 1673-1581
%D 2020
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1900719

TY - JOUR
T1 - Characteristics of chemotherapy-induced diabetes mellitus in acute lymphoblastic leukemia patients
A1 - Shan-shan Suo
A1 - Chen-ying Li
A1 - Yi Zhang
A1 - Jing-han Wang
A1 - Yin-jun Lou
A1 - Wen-juan Yu
A1 - Jie Jin
J0 - Journal of Zhejiang University Science B
VL - 21
IS - 9
SP - 740
EP - 744
%@ 1673-1581
Y1 - 2020
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1900719


Abstract: 
Acute lymphocytic leukemia (ALL) is one of the most common malignancies, especially in young people. Combination chemotherapy for ALL typically includes corticosteroids (Kantarjian et al., 2000). Hyperglycemia is a well-recognized complication of corticosteroids, and chemotherapy-induced diabetes (CID) is not uncommon (27.5%–37.0%) during the treatment of ALL (Hsu et al., 2002; Weiser et al., 2004; Alves et al., 2007). Besides the effect of corticosteroids, potential factors triggering hyperglycemia in ALL also include direct infiltration of the pancreas by leukemia cells and β cell dysfunction induced by chemotherapeutic agents such as L-asparagine (Mohn et al., 2004).

急性淋巴细胞白血病化疗继发糖尿病的临床特点

目的:明确急性淋巴细胞白血病(ALL)患者化疗期间继发糖尿病的发生率,探索发生继发糖尿病的危险因素及其对患者预后的影响.
创新点:继发糖尿病在ALL患者化疗期间常有发生,但其在不同化疗阶段的发生率、危险因素及其对患者预后的影响鲜有研究.本研究以此为切入点,探索了ALL患者化疗继发糖尿病的特点及其对患者预后的影响.
方法:收集浙江大学医学院附属第一医院血液科2011年1月至2013年10月期间收治的初发ALL病例共计177例,筛选出临床资料完整且入院时不合并糖尿病的患者156例.统计患者在诱导化疗期间和全化疗期间继发糖尿病的发生率,分析糖尿病组与非糖尿病组患者在总生存期、无事件生存期等方面的差异,并探讨继发糖尿病的危险因素.
结论:继发糖尿病是ALL患者化疗期间重要的并发症,年龄是化疗期间继发糖尿病的独立预测因子.对于年龄小于35岁的年轻患者,继发糖尿病患者相比于正常血糖者其总生存期和无事件生存期均缩短.

关键词:糖尿病;急性淋巴细胞白血病;临床特点

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Alves C, Chaves C, Souza M, 2007. Transient diabetes mellitus related to L-asparaginase therapy. Arq Bras Endocrinol Metabol, 51(4):635-638.

[2]American Diabetes Association, 2018. Updates to the Standards of Medical Care in Diabetes—2018. Diabetes Care, 41(9):2045-2047.

[3]Banihashem A, Ghasemi A, Ghaemi N, et al., 2014. Prevalence of transient hyperglycemia and diabetes mellitus in pediatric patients with acute leukemia. Iran J Ped Hematol Oncol, 4(1):5-10.

[4]Biondani G, Peyron JF, 2018. Metformin, an anti-diabetic drug to target leukemia. Front Endocrinol, 9:446.

[5]Chen WL, Wang JH, Zhao AH, et al., 2014. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood, 124(10):1645-1654.

[6]Chua LL, Rajasuriar R, Lim YAL, et al., 2020. Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy. BMC Cancer, 20:151.

[7]Gifford G, Milliken S, Greenfield J, 2013. Diabetic ketoacidosis secondary to L-asparaginase in acute lymphoblastic leukaemia. Intern Med J, 43(8):946-948.

[8]Giovannucci E, Harlan DM, Archer MC, et al., 2010. Diabetes and cancer: a consensus report. CA Cancer J Clin, 60(4):207-221.

[9]Hsu YJ, Chen YC, Ho CL, et al., 2002. Diabetic ketoacidosis and persistent hyperglycemia as long-term complications of L-asparaginase-induced pancreatitis. Chin Med J (Taipei), 65(9):441-445.

[10]Kantarjian HM, O'Brien S, Smith TL, et al., 2000. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol, 18(3):547.

[11]Koltin D, Sung L, Naqvi A, et al., 2012. Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics. Support Care Cancer, 20(9):2009-2015.

[12]Mohn A, di Marzio A, Capanna R, et al., 2004. Persistence of impaired pancreatic β-cell function in children treated for acute lymphoblastic leukaemia. Lancet, 363(9403):127-128.

[13]Ouyang J, Lin J, Isnard S, et al., 2020a. The bacterium Akkermansia muciniphila: a sentinel for gut permeability and its relevance to HIV-related inflammation. Front Immunol, 11:645.

[14]Ouyang J, Isnard S, Lin J, et al., 2020b. Metformin effect on gut microbiota: insights for HIV-related inflammation. AIDS Res Ther, 17:10.

[15]Rosilio C, Lounnas N, Nebout M, et al., 2013. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. Cancer Lett, 336(1):114-126.

[16]Thomas R, Wong WSW, Saadon R, et al., 2020. Gut microbial composition difference between pediatric ALL survivors and siblings. Pediatr Hematol Oncol, in press.

[17]Wang JH, Chen WL, Li JM, et al., 2013. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Proc Natl Acad Sci USA, 110(42):17017-17022.

[18]Weiser MA, Cabanillas ME, Konopleva M, et al., 2004. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer, 100(6):1179-1185.

[19]Zi FM, He JS, Li Y, et al., 2015. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Cancer Lett, 356(2):443-453.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE